The role of circRNAs and miRNAs in drug resistance and targeted therapy responses in breast cancer [0.03%]
circRNA和miRNA在乳腺癌耐药及靶向治疗反应中的作用
Meilan Zhang,Zhaokuan Zheng,Shouliang Wang et al.
Meilan Zhang et al.
MicroRNAs (miRNAs) are small non-coding RNAs comprising 19-24 nucleotides that indirectly control gene expression. In contrast to other non-coding RNAs (ncRNAs), circular RNAs (circRNAs) are defined by their covalently closed loops, forming...
Impact of genetic variants in the solute carrier (SLC) genes encoding drug uptake transporters on the response to anticancer chemotherapy [0.03%]
药物摄取转运蛋白溶质载体(SLC)基因多态性与抗肿瘤化疗疗效关系研究进展
Jose J G Marin,Maria A Serrano,Elisa Herraez et al.
Jose J G Marin et al.
Cancer drug resistance constitutes a severe limitation for the satisfactory outcome of these patients. This is a complex problem due to the co-existence in cancer cells of multiple and synergistic mechanisms of chemoresistance (MOC). These ...
Yixia Liang,Guo Wu,Jiabao Tan et al.
Yixia Liang et al.
Neutrophils are recognized active participants in inflammatory responses and are intricately linked to cancer progression. In response to inflammatory stimuli, neutrophils become activated, releasing neutrophils extracellular traps (NETs) f...
Inhibition of glutaminolysis alone and in combination with HDAC inhibitor has anti-myeloma therapeutic effects [0.03%]
单纯抑制谷氨酰胺代谢及与组蛋白脱乙酰基酶抑制剂联合应用对多发性骨髓瘤的治疗作用
Seiichi Okabe,Yuko Tanaka,Mitsuru Moriyama et al.
Seiichi Okabe et al.
Aim: This study aimed to investigate drug candidates and their efficacy in treating refractory multiple myeloma (MM) despite significant therapeutic advances and the introduction of novel agents. Our study focused on how myeloma cells media...
Recent advanced lipid-based nanomedicines for overcoming cancer resistance [0.03%]
近年基于脂质的纳米药物克服肿瘤耐药性的进展
Piroonrat Dechbumroong,Runjing Hu,Wisawat Keaswejjareansuk et al.
Piroonrat Dechbumroong et al.
The increasing prevalence of cancer drug resistance not only critically limits the efficiency of traditional therapies but also causes relapses or recurrences of cancer. Consequently, there remains an urgent need to address the intricate la...
Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancer [0.03%]
抗HER2抗体药物偶联物的作用机制及其耐药性在乳腺癌中的作用
Khalil Saleh,Rita Khoury,Nadine Khalife et al.
Khalil Saleh et al.
Human epidermal growth factor 2 (HER2)-positive breast cancer (BC) represents nearly 20% of all breast tumors. Historically, these patients had a high rate of relapse and dismal prognosis. The advent of HER2-targeting monoclonal antibodies ...
Unraveling the complexity of drug resistance mechanisms to SINE, T cell-engaging therapies and CELMoDs in multiple myeloma: a comprehensive review [0.03%]
解码药物耐药机制的复杂性：SINE、T细胞靶向疗法和CELMoDs在多发性骨髓瘤治疗中的作用——全面综述
Jacqueline Schütt,Kerstin Brinkert,Andrzej Plis et al.
Jacqueline Schütt et al.
Despite significant advances in the understanding of multiple myeloma (MM) biology and the development of novel treatment strategies in the last two decades, MM is still an incurable disease. Novel drugs with alternative mechanisms of actio...
The evolving role of immune checkpoint inhibitors in cervical and endometrial cancer [0.03%]
免疫检查点抑制剂在宫颈癌和子宫内膜癌中作用的演变
Bertha Alejandra Martinez-Cannon,Ilaria Colombo
Bertha Alejandra Martinez-Cannon
The introduction of immune checkpoint inhibitors (ICIs) has revolutionized the treatment landscape for numerous tumor types, including cervical and endometrial cancers. Multiple ICIs against programmed cell death-1 (PD-1), programmed death-...
Validation of single nucleotide polymorphisms potentially related to R-CHOP resistance in diffuse large B-cell lymphoma patients [0.03%]
验证弥漫性大B细胞淋巴瘤患者潜在的与R-CHOP耐药相关的单核苷酸多态性
Gabriele Perrone,Luigi Rigacci,Giandomenico Roviello et al.
Gabriele Perrone et al.
Aim: Diffuse large B-cell lymphoma (DLBCL) is the most common B-cell non-Hodgkin lymphoma (NHL). Despite the availability of clinical and molecular algorithms applied for the prediction of prognosis, in up to 30%-40% of patients, intrinsic ...
HER3-targeted therapy: the mechanism of drug resistance and the development of anticancer drugs [0.03%]
her3靶向治疗：耐药机制及抗癌药物研发
Huilan Zeng,Wei Wang,Lin Zhang et al.
Huilan Zeng et al.
Human epidermal growth factor receptor 3 (HER3), which is part of the HER family, is aberrantly expressed in various human cancers. Since HER3 only has weak tyrosine kinase activity, when HER3 ligand neuregulin 1 (NRG1) or neuregulin 2 (NRG...